A

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Today, however, we will be daydreaming about a week-long respite. Yes, the time has come to disappear for a few days, although a colleague or two will assume Pharmalittle duties in our absence. And what about you? Any sojourns planned? This is a lovely time to enjoy the great outdoors or take an excursion. Well, whatever you do, have a grand time. But, be safe. See you all soon …

The first new drug for amyotrophic lateral sclerosis, or ALS, in 22 years was approved by U.S. regulators this week, causing excitement but also concerns, ABC News reports. Some physicians worry about the cost for Radicava — about $146,000 per year — as well as misconceptions about how effective the drug will be at fighting the degenerative condition  and that numerous infusions mean many such trips for patients with reduced mobility.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.